Clinical results with the Resolute zotarolimus-eluting stent in total coronary occlusions

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F15%3A43909181" target="_blank" >RIV/00216208:11120/15:43909181 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064173:_____/15:N0000001

Výsledek na webu

<a href="http://dx.doi.org/10.4244/eijy14m07_14" target="_blank" >http://dx.doi.org/10.4244/eijy14m07_14</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4244/eijy14m07_14" target="_blank" >10.4244/eijy14m07_14</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Clinical results with the Resolute zotarolimus-eluting stent in total coronary occlusions

Popis výsledku v původním jazyce

Aims: We conducted a pooled post hoc analysis (RESOLUTE All Comers and RESOLUTE International) of patients who had the Resolute(R) zotarolimus-eluting stent (R-ZES) implanted in revascularised total occlusions (TO) compared with patients treated with R-ZES for non-occluded lesions. Methods and results: Patients were divided into three groups: chronic TO (CTO; n=256), non-chronic TO (n=292), and no occlusion (n=2,941). Clinical and safety outcomes assessed through two years included target lesion failure(TLF: cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularisation) and Academic Research Consortium definite or probable stent thrombosis. The rate of TLF at two years was not significantly different among patients in the CTO (9.1%), TO (9.8%), and no occlusion (10.4%) groups (log-rank p=0.800); neither were the components of TLF. Definite or probable stent thrombosis occurred more frequently in the TO group (2.8% vs. 1.2% in the CTO and 1.1

Název v anglickém jazyce

Clinical results with the Resolute zotarolimus-eluting stent in total coronary occlusions

Popis výsledku anglicky

Aims: We conducted a pooled post hoc analysis (RESOLUTE All Comers and RESOLUTE International) of patients who had the Resolute(R) zotarolimus-eluting stent (R-ZES) implanted in revascularised total occlusions (TO) compared with patients treated with R-ZES for non-occluded lesions. Methods and results: Patients were divided into three groups: chronic TO (CTO; n=256), non-chronic TO (n=292), and no occlusion (n=2,941). Clinical and safety outcomes assessed through two years included target lesion failure(TLF: cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularisation) and Academic Research Consortium definite or probable stent thrombosis. The rate of TLF at two years was not significantly different among patients in the CTO (9.1%), TO (9.8%), and no occlusion (10.4%) groups (log-rank p=0.800); neither were the components of TLF. Definite or probable stent thrombosis occurred more frequently in the TO group (2.8% vs. 1.2% in the CTO and 1.1

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

EuroIntervention

ISSN

1774-024X

e-ISSN

—

Svazek periodika

11

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

FR - Francouzská republika

Počet stran výsledku

8

Strana od-do

650-657

Kód UT WoS článku

000365143500008

EID výsledku v databázi Scopus

—